Skip to main content

Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Table 1 Demographic characteristics of the patients, ANA status at baseline and characteristics of the infusion reactions

From: Predictors of infusion reactions during infliximab treatment in patients with arthritis

Characteristic RA (n = 213) SpAs (n = 76)
Age at inclusion (years) 55.9 ± 14.0 45.0 ± 13.1
Age at disease onset (years) 43.2 ± 15.2 31.9 ± 13.1
Disease duration at start (years) 12.6 ± 10.0 13.1 ± 11.0
Treatment duration at infusion reaction (months) 11.5 ± 9.6 4.3 ± 4.3
Number of previous DMARDs 3.3 ± 1.7 1.9 ± 1.1
Female 156 (73.2%) 40 (52.6%)
ANA positivity (yes) 56/201 (27.9%) 18/72 (25.0%)
Infusion reaction (yes) 45 (21.1%) 10 (13.2%)
Infusion reaction leading to withdrawal of treatment 33/45 (73.3 %) 9/10 (90%)
  1. Values are expressed as mean ± standard deviation or as number (%). ANA, antinuclear antibody; DMARD, disease-modifying antirheumatic drug.